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Background: Due to their modular repeat structure, Pumilio/fem-3 mRNA binding factor (PUF) proteins are
promising candidates for designer RNA-binding protein (RBP) engineering. To further facilitate the application of
the PUF domain for the sequence-specific RBP engineering, a rapid cloning approach is desirable that would allow
efficient introduction of multiple key amino acid mutations in the protein. Here, we report the implementation of
the Golden Gate cloning method for an efficient one-step assembly of a designer PUF domain for RNA specificity
engineering.
Results: We created a repeat module library that is potentially capable of generating a PUF domain with any
desired specificity. PUF domains with multiple repeat modifications for the recognition of altered RNA targets were
obtained in a one-step assembly reaction, which was found to be highly efficient. The new PUF variants exhibited
high in vitro binding efficiencies to cognate RNA sequences, corroborating the applicability of the modular approach
for PUF engineering. To demonstrate the application of the PUF domain assembly method for RBP engineering, we
fused the PUF domain to a post-transcriptional regulator and observed a sequence-specific reporter and endogenous
gene repression in human cell lines.
Conclusions: The Golden Gate based cloning approach thus should allow greater flexibility and speed in
implementing the PUF protein scaffold for engineering designer RBPs, and facilitate its use as a tool in basic and
applied biology and medicine.
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Golden GateBackground
The presence of RNA-binding proteins (RBPs) in RNA
biology is ubiquitous. Hundreds to thousands of eukaryotic
proteins are estimated to function as RBPs [1] and govern
many aspects of RNA biology including translation, turn-
over, processing, and cellular localization [2-4]. Despite
their great diversity in function, only a few types of
RNA-binding domains are known, which are combined
in different structural arrangements with a variety of
functional domains [5]. This modular architecture makes* Correspondence: zhao5@illinois.edu
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unless otherwise stated.RBPs an attractive tool for studying the vast complexity of
eukaryotic transcriptomes as well as manipulating RNA
for therapeutic purposes [6,7].
The function of many RBPs can be studied [8-11] by
tethering them to a reporter RNA through a well-
characterized RNA-binding peptide with a fixed specifi-
city [12]. However, this approach can only be applied to
manipulate heterologous RNA because prior tagging of
the RNA is required. In order to manipulate endogenous
RNA in its native expression conditions, one could envi-
sion a designer RBP with an RNA-binding scaffold that
could be easily engineered for sequence specificity. To
date, only pentatricopeptide repeat [13,14] and Pumilio/
fem-3 mRNA binding factor (PUF) [15-18] proteins have
been demonstrated to have the potential to be rationally
modified for predictable and specific RNA recognition.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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post-transcriptional gene regulation [19]. The crystal
structure of Pumilio homology domain (PUM-HD), the
RNA-binding region of the human Pumilio 1 (PUM1)
protein (Figure 1a), reveals 8 structural repeats, each
containing ~36 amino acids (aa), and flanking N-and
C-terminal regions [20,21]. The structure also suggests
that recognition of the target RNA sequence is highly
modular since each repeat binds to a single RNA base
[15]. The N-terminal repeat (R1) binds to the 3′-nucleo-
tide residue (N8) of the target sequence (Figure 1a and b),
while the C-terminal repeat (R8) binds to the 5′-nucleo-
tide residue (N1). Residues at positions 12 and 16 in each




Figure 1 The GG library and assembly schematic. (a) Crystal structure o
code 1M8Y. (b) Schematic of PUM-HD bound to RNA. Filled boxes, PUF mod
repeat modules, with matching overhangs colored in identical colors; 4 variat
above; the aa sequence of module 2, with mutant aa indicated in red; and tw
that contains 8 modules of choice, a receiving vector, and enzymes allows th
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modules recognizing A, G, U, and C, respectively.base, whereas the residue at position 13 is involved in a
stacking interaction between two adjacent bases [15]. The
structure suggests a recognition “code”, where residues at
positions 12 and 16 in each repeat contribute to specific
recognition of a base, with N12Q16 recognizing uracil,
C12Q16 adenine, and S12E16 guanine [15]. The residue
combination S12R16 was engineered to recognize cytosine
[17,18]. By swapping the key residues at these positions, it
was shown that designed PUF proteins with altered speci-
ficity could be engineered [16,22]. In the past several
years, engineered PUF domains were successfully fused
to different effector domains for polyadenylation of
an endogenous gene or repression of a reporter gene
in Xenopus [23], cleavage of a mitochondrial-encoded genee
f PUM-HD bound to RNA, adapted from reference [15], GenBank ID
ules. Circles, RNA bases. (c) Schematic of the main library components: 8
ions of module 2, with corresponding recognition nucleotide indicated
o receiving vectors. (d) The GG assembly schematic. A one-pot reaction
e creation of 9 unique overhangs. The exact matching of the overhangs
(e) Schematic of the GG library. R, module; N, nucleotide; recognized
names represent aa residues 12 and 16, in each module, respectively.
es. Red font, mutant modules. Green, yellow, pink, and blue fillings for
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Bcl-X pre-mRNA in human cells [25], and imaging
endogenous RNA [26-28]. These advancements demon-
strate the growing potential for the RBPs with various
functional domains and engineered specificity.
However, PUF-based RBPs are still far from wide-
spread implementation. One of the limitations in engin-
eering PUF domains with novel specificities is the lack
of a cloning platform capable of rapid and efficient
introduction of multiple mutations in separate repeats
simultaneously. In this study, we report the implementa-
tion of the Golden Gate (GG) cloning, Type IIS restric-
tion endonuclease-based approach [29] for engineering
of PUF-based RBPs. To demonstrate the efficiency of
this approach, we first used this cloning method for con-
struction of several mutant PUF domains with novel
specificities and assayed their binding affinities. Second,
we linked the RNA-binding activity of engineered PUF
domains to the translational repression activity of triste-
traprolin (TTP), and used the fusion protein in a func-
tional reporter system to assay the PUF domain activity in
HeLa cells. Finally, we showed the application of the engi-
neered TTP-PUF fusion proteins for the post-transcriptional
regulation of an endogenous gene in HEK293 cells.
Results and discussion
Efficient assembly of a custom-designed PUF domain
The GG cloning method, which is implemented here for
the assembly of custom PUF domains, is based on the
ability of Type IIS restriction enzymes to cleave outside
of their non-palindromic recognition sequence [29], thus
creating overhangs unrelated to the recognition se-
quence. This polarity and flexibility in the overhang se-
quence allows for a seamless removal of the original
restriction site as well as a ligation of multiple fragments
in one step.
As a scaffold for the development of the assembly
toolkit, we used the human PUM-HD, which consists of
the amino acids 828-1176 of the full-length PUM1 [21].
Each of the 8 structural repeats of PUM-HD was cloned
individually into a pNEB193-based “intermediate vector”
and was used as a separate assembly module (Figure 1c).
We designed all 8 modules as well as the lacZα gene in
the “receiving vector” to be flanked by two BsaI sites in
such a way that would allow creation of 9 unique over-
hangs (Figure 1c). In a one-pot reaction, the 8 modules
and the receiving vector can be efficiently cut and re-
ligated in a predefined order (Figure 1d).
These 8 modules were further expanded into a library
where each module has 4 variations for the recognition
of any of the 4 nucleotides (nt), consistent with the PUF
recognition “code” [15,17,18]. The variants of the same
module position have the same overhangs and the same
amino acids as the wild type (WT) module except atpositions 12 and 16 (Figure 1c). The introduced muta-
tions are uniform across modules (Figure 1e), except for
module 7 for the recognition of cytosine, where the
“stacking” residue was also substituted with tyrosine, in
accordance with a previous report by Dong et al. [18].
Since module 3S12R16 requires a tyrosine as a “stacking”
residue in the adjacent module 4 for in vivo activity [18],
four additional module 4 variants were created, where
the “stacking” residue at position 13 was mutated from
histidine to tyrosine.
Finally, we constructed two receiving vectors, pET28-
GG-PUF for Escherichia coli expression and pCMV-TTP
(C147R)-GG-PUF for mammalian expression. They both
contain a lacZα gene for easy identification of assembled
clones using blue-white screening, as well as the flanking
N- and C-terminal regions of PUM-HD, which we refer
to as R1′ and R8′, respectively. The entire library hence
consists of 36 intermediate vectors and 2 receiving vec-
tors. Thus, our library of PUF repeat modules is poten-
tially capable of a one-step assembly of PUF domains
with specificity for any RNA sequence of 8 nt, given that
they can be expressed in a soluble manner.
In order to test the efficiency of the method, we re-
assembled the original PUM-HD from the WT modules
into both receiving vectors. We analyzed 10 randomly
chosen clones from each assembly by restriction diges-
tion and found that all produced the anticipated diges-
tion pattern (Additional file 1: Figure S1a and b). Next,
we sequenced one clone from each assembly and found
that both sequences were correct, indicating that the as-
sembly process is highly efficient regardless of a receiv-
ing vector. Assembly of the consecutive mutant PUF
domains was as efficient as the assembly of the WT PUF
domain (data not shown). The entire process takes
3 days, with the GG reaction and E. coli transformation
on day 1, colony picking on day 2, and plasmid purifica-
tion and digestion-confirmation of the clones on day 3.
The procedure is therefore ideal for the rapid introduc-
tion of multiple mutations in a PUF domain with high
efficiency.
Binding activity of custom-designed PUF domains in vitro
With the combinatorial assembly tool in hand, we set to
determine if increasing the number of mutations affects
the activity or specificity of a PUF domain. We assem-
bled four variant PUF domains with 2, 4, 6, and 8 mu-
tant modules that were named PUF (S2), PUF (S4), PUF
(S6), and PUF (S8), respectively (Table 1). To test their
in vitro activity, we assayed the binding affinity of the
proteins to WT and their cognate RNA sequences using
a fluorescence polarization assay (Additional file 1:
Figure S2b-f ). We found that the WT PUF as well as
the PUF variants all bound to their cognate RNA se-
quences with high affinity (Table 1). As predicted, all
Table 1 Mutations, cognate and noncognate RNA oligonucleotide sequences, and binding affinities of PUF (WT), and
PUFs S2-S8
Protein Protein modules Cognate RNA sequence KD, nM Noncognate RNA sequence KD, nM
Ct 8 – 7 – 6 – 5 – 4 – 3 – 2 – 1 Nt 5′ 1 2 3 4 5 6 7 8 3′ 5′ 1 2 3 4 5 6 7 8 3′
PUF(WT) NQ-SE-NQ-CQ-NQ-CQ-NQ-SQ CCAGAAU/UGUAUAUA/UUCG 0.043±0.023 CCAGAAU/AGUAUAUU/AUUCG 3.56±0.90
PUF (S2) CQ-SE-NQ-CQ-NQ-CQ-NQ-NQ CCAGAAU/AGUAUAUU/AUUCG 0.76±0.11 CCAGAAU/UGUAUAUA/UUCG 6.29±2.80
PUF (S4) NQ-SE-CQ-NQ-CYQ-NQ-NQ-SQ CCAGAAU/UGAUAUUA/UUCG 0.59±0.10 CCAGAAU/UGUAUAUA/UUCG 5.77±1.33
PUF (S6) CQ-SE-CQ-NQ-CYQ-NQ-NQ-NQ CCAGAAU/AGAUAUUU/UUCG 6.05±0.25 CCAGAAU/UGUAUAUA/UUCG 89.6±16.5
PUF (S8) CQ-NQ-CQ-NQ-CYQ-NQ-SE-NQ CCAGAAU/AUAUAUGU/UUCG 2.79±0.69 CCAGAAU/UGUAUAUA/UUCG ND
Bold, mutant modules and changed RNA bases compared with the WT target sequence. Target RNA sequences are delimitated by forward slashes. Ct, C-terminus,
and Nt, N-terminus of the protein. KD values were determined using nonlinear curve fitting and represent the mean ± SD (n = 3). ND, KD not determined due to
little binding at 300 nM PUF (S8) to WT RNA.
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nate RNA, which contained between 2 and 8 nucleo-
tide mismatches with the cognate RNA (Table 1,
Additional file 1: Figure S2b-f ). The binding affinities
to cognate sequences decreased from PUF (WT) to
PUF (S8), indicating that there is a weak negative cor-
relation between the number of mutations and binding
affinity to cognate RNA, although the correlation is
not strictly linear (Table 1). However, even PUF (S8),
which has 8/8 mutant modules, binds specifically and
with high affinity to its cognate RNA. These results
further corroborate the study by Cheong and Hall,
who demonstrated the specificity and modularity of
PUF protein target recognition [16].
Engineering and assessment of designer repressor-RBP,
TPUF
As an example of PUF-based RBP engineering, we fused
the PUM-HD domain to TTP, a well-studied post-
transcriptional regulator. TTP binds to AU-rich ele-
ments (AREs) in the 3′-untranslated region (UTR) of
the target genes and promotes mRNA degradation by
recruiting a deadenylase complex [30]. TTP is also known
to promote ARE-dependent gene knockdown via transla-
tion repression through cooperation with a general trans-
lation inhibitor RCK/P54 [31], though the details of this
mechanism remain unknown. We reasoned that the
RNA-binding activity of TTP was undesirable due to pos-
sible interference of TTP towards efficient binding of PUF
to PUF-binding sites (PBSs). We therefore introduced the
C147R mutation that was shown to abolish the bind-
ing of TTP to ARE [32]. TTP (C147R) was fused to
the N-terminus of PUM-HD through a (G4S)3G4 linker
and expressed in HeLa cells for functional analysis
(Additional file 1: Figure S3a).
To assay the gene repression activity of TTP-PUF fu-
sion constructs, a dual luciferase assay was implemented.
To the 3′ UTR of the firefly luciferase (FL) reporter, 10
PBSs separated by 6-18 nt were cloned (Additional file 1:
Figure S3 b). Renilla luciferase (RL) lacking any PBSs was
co-transfected with FL as a transfection control. FLRandom,also lacking any PBSs, was used as a repression control.
Values of FLPBS/RL normalized to FLRandom/RL were re-
ported as “relative FL/RL activity.” We observed that TTP
(C147R) alone did not significantly repress the FLPBS (WT)
activity, whereas PUM-HD (WT) alone repressed
FLPBS (WT) by 20%. The observed weak activity of
PUM-HD RNA-binding motif alone can be explained
by previous findings that the Pumilio RNA-binding
domain is also a translational regulator that is capable of
recruiting deadenylases to the concave surface of repeats 7
and 8 [33]. However, the TTP (C147R)-PUM-HD (WT)
fusion construct (hereafter referred to as TPUF (WT))
repressed the FLPBS (WT) activity by 80% (Figure 2a), thus
demonstrating that the fusion construct exhibits both
specific RNA binding and high repression activity.
We also tested the repression levels of FL containing 1,
3, and 5 PBSs in the 3′ UTR (Additional file 1: Figure S4)
and observed repression activity of TPUF (WT) ranging
between 31-55%. However, to obtain the greatest dynamic
range of our reporter assay, we conducted consequent
experiments using 10 PBSs. Although using 10 PBSs is in
contrast compared with those using 1 PBS in previous
assays [23], it is comparable to using 5-6 binding sites in
tethering assays of TTP and other ARE-mediated decay
activation domains [31,34,35].
To determine if the TPUF (WT) construct functions
by promoting degradation of target RNA, we performed
real-time PCR (RT-PCR) analysis on the FL reporter,
and used RL as the internal control. We did not observe
decrease in RNA levels in FLPBS (WT) compared with
FLRandom in the presence of TPUF (WT) (Additional file 1:
Figure S5). Several FL RT-PCR primer pairs were used,
and consistently no RNA destabilization was observed
(data not shown). These results are in accordance with a
similar TTP tethering assay [31], where luciferase activity
was knocked down despite little RNA destabilization. We
suggest that the TPUF constructs function similarly, by
promoting translational repression rather than RNA deg-
radation [31].
To further test the design concept, we used our GG





Figure 2 Various TPUF repression activity assessment in HeLa cell line. (a) Dual luciferase assay shows that TPUF (WT), a fusion of TTP
(C147R) and PUM-HD (WT), exhibits the greatest down-regulation activity on FLPBS (WT) expression, compared with TTP and PUM-HD (WT) alone.
Data represented as mean fold change relative to cells transfected with FLRandom (dashed line, unrepressed FL/RL activity) ± SD: n.s., not significant,
***P≤ 0.001 (n = 3, t test). (b) Luciferase assay shows predicted specificity of previously reported PUF mutants [16]. TPUF (WT) prefers PBS (WT),
TPUF (1SE) prefers PBS (A8G), and TPUF (6SE,7NQ) prefers PBS (GU/UG). Data represent means ± SD: n.s., not significant, **P≤ 0.01, ***P≤ 0.001
(n = 3, t test). (c) Mutations and PBSs of TPUFs A-E with 3-4 randomly chosen mutant modules. Black, WT PUF modules and corresponding RNA
bases. Red, mutant PUF modules and corresponding RNA bases. Ct, C-terminus, Nt, N-terminus of the protein. (d) A graph of luciferase activity,
where TPUFs A-E repress FLs with cognate PBSs. Data represent means ± SD: **P≤ 0.01, ***P≤ 0.001 (n = 3, t test). (e)Western blot of effector proteins
using anti-Flag antibody shows no major difference in the expression. Anti-α–tubulin antibody was used as a loading control.
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of G8 [PBS (A8G)], and TPUF (6SE,7NQ) has repeats 6
and 7 replaced for the recognition of G and U at posi-
tions 2 and 3, respectively [PBS (GU/UG)]. TPUF (WT)
and the two PUF variants exhibited highest repression
activities towards their cognate PBSs, with repression
levels of 76%, 79%, and 88%, respectively. Compared
with cognate PBSs, we observed a diminished activity to-
wards PBSs with 1 or 2 mismatches, though some cross-
reactivity is evident (Figure 2b). These observations are
consistent with the cross-reactivity between WT and
PUF (1SE) in in vitro assays [16] and similar cross-
reactivity between WT and other mutant PUF proteins
[16,25] that differ by 1-2 repeats. Overall, luciferase re-
pression by the TPUF constructs was sequence-specific,
corroborating the validity of the TPUF-reporter system.
In order to further verify the functionality of the clon-
ing method and the TPUF platform, we assembled more
TPUF constructs with mutant repeats randomly intro-
duced throughout the PUF domain (Figure 3c), denotedas TPUFs A-E. Out of 5 TPUF variants, only TPUF (B)
showed low (17%) repression activity towards a cognate
PBS, whereas TPUFs A, C-E showed repression activities
ranging from 43% to 75% (Figure 3d). TPUFs with all 8
replaced modules demonstrated poor repression activ-
ities (data not shown), indicating that accumulation of
mutations in the PUF domain does not always result in
active TPUF proteins in vivo.
The difference between TPUF activities in a cell line
could be dependent on the expression and solubility
levels of the fusion proteins. We therefore investigated
soluble expression levels of all of the effector proteins
mentioned above using Western blotting (Figure 2e).
We found that TTP, PUM-HD, and TPUF (WT), as well
as mutants TPUF (1SE) and TPUF (6SE,7NQ) were
expressed at similar levels, thus excluding the possibility
of protein abundance variability distorting the observed
repression activities. On the other hand, we noticed
some noticeable variability among soluble expression
levels of TPUFs (A-E). However, this variability does not
ab c
d
Figure 3 TPUF represses endogenously expressed VEGFA gene in HEK293 cell line. (a) Mutations and binding sequences of TPUFs
designed for VEGFA 3′ UTR recognition. Black, WT modules and corresponding RNA bases. Red, mutant modules and corresponding RNA bases.
Blue, a mismatch in the recognition sequence. Ct, C-terminus, Nt, N-terminus of the protein. (b) The graph demonstrates inhibition of hypoxia-induced
VEGFA expression in cells transfected with engineered TPUFs VEGF3 and VEGF7. In hypoxic (+) cultures, VEGFA expression was induced with 500 μM CoCl2
24 hours after transfection and then cultivated for 24 hours. Secreted VEGFA levels measured by ELISA were normalized to total protein amounts from
lysed cells measured by Bradford Assay. Data represented as mean ± SD: n.s., not significant, *P≤ 0.05, **P≤ 0.01, (n = 3, t test). (c) The graph demonstrates
inhibition of DHB-induced VEGFA expression in cells transfected with TPUFs WT, VEGF1, VEGF3, and VEGF7. HEK293 cells with the integrated V24P-GS60
transcriptional activator of endogenous VEGFA promoter were treated with 100 nM DHB 24 hours after TPUF transfection and then cultivated for 24 hours.
ELISA and normalization to total protein amounts as in the previous panel. Data represented as mean ± SD: n.s., not significant, *P ≤ 0.05. (d) Western
blot of effector proteins using anti-Flag antibody shows greater expression of TPUFs VEGF3 and VEGF7 compared with TPUF (WT) and other
mutants. Anti-α–tubulin antibody was used as a loading control.
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In particular, it does not explain the apparent lower ac-
tivities of TPUF (B) and TPUF (E).
We conclude that in vivo TPUF activities must be
dependent on various other factors in addition to pro-
tein stability. For example, unequal contributions of dif-
ferent repeat-base interactions to the binding energy of
the RNA-protein complexes [16,36] may result in different
overall binding affinities to cognate RNA. In addition,
binding to noncognate RNA [37] could allow sequestra-
tion of the protein to non-target RNA in vivo. Finally,
sporadic domain interactions in fusion proteins could
interfere with RNA binding. We cannot yet predict the
contribution of each of these factors on PUF activity
in vivo, and therefore suggest that the effects of these and
other factors on engineered PUF activity have to be sys-
tematically investigated.
Endogenous gene regulation using TPUF
As a proof of concept for implementing designer RBP
for endogenous gene regulation, we designed TPUFs that
bind to the 3′ UTR of human vascular endothelial
growth factor-A (VEGFA) mRNA. VEGFA is one of thecentral mediators of angiogenesis, and was shown to be
overexpressed in many human tumors. VEGFA is up-
regulated in these tumors under hypoxic growth condi-
tions that many tumors create [38]. As such, VEGFA is
an attractive target for the development of therapeutics
to inhibit pathological angiogenesis. We reasoned that
for our TPUF repression assay, elevated VEGFA levels
are more therapeutically relevant than physiological
lower levels, and therefore employed two different strat-
egies to up-regulate endogenous VEGFA expression. In
the first strategy, we incubated HEK293 cells with μM
500 CoCl2, an agent that causes conditions mimicking
hypoxia [39], and achieved an 8-fold VEGFA induction
compared to cells grown in the absence of the agent
(Figure 3b). In the second strategy, we used a HEK293
cell line in which a small molecule-responsive gene
switch for VEGFA expression was stably integrated [40].
Upon induction with 4,4′-dihydroxybenzyl (DHB), en-
dogenous VEGFA was up-regulated 19-fold.
For the post-transcriptional down-regulation of
VEGFA, we assembled TPUFs VEGF1, VEGF3, and
VEGF7 (Figure 3a), which have, respectively, 1, 3, and 7
PBSs in the 3′ UTR of all known transcript variants of
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VEGF7 constructs each carry one mutant repeat and
were previously reported to be active in vitro [16]. TPUF
(VEGF1) has repeats 6 and 7 replaced for the recogni-
tion of 2A and 3C in the PBS. WT repeat 4N12Q16 was
left unchanged for the recognition of 5G (Figure 3a,
blue), since this repeat is known to be promiscuous [41].
TPUF (S4) was shown to be active for its cognate RNA
using the luciferase assay (Additional file 1: Figure S6);
however, it does not have binding sites in the 3′UTR of
VEGFA mRNA, and therefore was not expected to re-
press the gene. Fortuitously, PBS (WT) is present 3
times in the 3′ UTR of VEGFA mRNA, which allowed
us to use TPUF (WT) as a reference for assaying activ-
ities of mutant TPUFs.
To assay the repression activity, we transiently trans-
fected recombinant HEK293 cells with equimolar amounts
of GFP or one of the TPUF constructs, induced the expres-
sion of VEGFA 24 hours after transfection, and assayed se-
creted levels of VEGFA by ELISA 24 hours after induction.
VEGFA levels were normalized to total protein concentra-
tion, which we assumed to correlate with cell number.
Bradford Assay was used to measure the total protein con-
centrations from cell lysates. We found that VEGFA
amounted to less than 1% of total protein concentration by
mass (Figure 3b and c), hence the variations of VEGFA
concentrations in the cell would have no significant effect
on total protein concentration. In both induction strat-
egies, the VEGFA levels were not significantly affected by
TPUF (S4) compared to samples transfected with GFP, as
expected (Figure 3b and c). In cells treated with CoCl2,
only TPUF (VEGF3) and TPUF (VEGF7) significantly re-
pressed VEGFA expression, which was down-regulated by
38% and 57%, respectively (Figure 3b). On the other hand,
in cells induced with DHB, TPUF (WT) caused consider-
able (44%) repression of VEGFA, whereas TPUFs VEGF1,
VEGF3, and VEGF7 knocked down VEGFA levels by 55%,
77%, and 74%, respectively (Figure 3c). We are currently
unaware of the reason why cells exposed to hypoxia were
more resistant to VEGFA repression by our TPUF con-
structs compared with cells that expressed the gene switch.
We speculate that it could be due to yet undiscovered tran-
scriptional and/or translational gene regulatory response of
cells to hypoxia. Increasing the TPUF expression time to
41 hours and decreasing exposure to hypoxia to 7 hours
resulted in similar repression levels as in the previous con-
ditions (data not shown), and therefore we exclude the
possibility that this resistance is simply due to lower ex-
pression of TPUFs at hypoxia. The lower TPUF activity at
hypoxia might hence be due to an unknown interference
with TTP function. Nevertheless, we observed a consider-
able sequence-specific down-regulation of VEGFA in cells
expressing the VEGFA transcriptional gene switch, and
confirmed the efficacy of the TPUF platform in the down-regulation of an endogenous gene in human cells as yet an-
other demonstration of the applicability of PUF-based
RBPs at post-transcriptional gene regulation [23,24].
To compare the expression levels of TPUF constructs
among each other, we performed a Western blot analysis
of the effector proteins under normoxia (Figure 3d). We
observed a substantially greater soluble expression of
TPUF (VEGF3) and TPUF (VEGF7) which might be the
main reason of these constructs’ higher overall activity.
These VEGFA repression levels are comparable to
those in similar assays conducted with zinc finger tran-
scriptional repressors or small interfering RNA (siRNA).
For example, hypoxia-induced VEGFA protein levels in
HEK293 cells were knocked down by 74% by an engi-
neered zinc finger transcriptional repressor [42] and
VEGFA mRNA was knocked down by 50% by another
zinc finger repressor in HEK293 cells grown in normoxia
[43]. On the other hand, siRNA knocked down endogen-
ous VEGFA by up to 43% in ID8 cells [44] and up to
71% in hypoxic HEK293 cells [42]. Thus, the TPUF sys-
tem that we have engineered is as effective as some
other existing technologies that are often used to knock
down gene expression levels, and can be a powerful
alternative.
Based on these findings, we conclude that the imple-
mentation of TPUFs for down-regulation of other en-
dogenous genes with high efficacy is possible. However,
factors determining tight binding of Pumilio domains to
RNA in vitro, as well as factors determining high in vivo
activities are still largely unknown, and a systematic in-
vestigation is needed. For example, based on the results
reported above, either effective target site recognition or
protein stability may play a major role in a protein’s
functional efficacy in vivo in any given mutant. It is diffi-
cult, at this stage, to predict which contribution would
predominate. In vitro RNA binding affinities and in vivo
activities show only a rough correlation [23,25], and sol-
uble expression levels do not always predict activity dif-
ferences (Figure 2d and e). Therefore, for engineering of
TPUFs with novel specificities or PUM-HD-based pro-
teins with novel functionalities, we recommend building
a reporter system suitable for the given protein activity,
and directly screening the functional efficacy of the as-
sembled PUF variants.
Conclusions
In this study, we established a toolkit for rapid engineer-
ing of designer RBPs that can be used for manipulation
of endogenous genes. This approach should allow greater
flexibility and speed at creating PUF domains with user-
defined specificities and thus facilitate the use of PUF-
based designer RBPs as a tool in research and therapeutics.
We demonstrated that PUF mutants with as many as 8/8
mutant modules can be cloned with high efficiency and
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affinity to their cognate RNA in vitro. This result is consist-
ent with the study by Cheong and Hall [16] and confirms
the RNA recognition code and modularity of PUF do-
mains. Finally, we were able to demonstrate the implemen-
tation of the protein-based post-transcriptional repressor
for down-regulation of an endogenous gene. The TPUF
platform introduced in this work exhibits modular and
sequence-specific recognition and down-regulation of
genes. We envision the future development of PUF-based
RBPs with various functionalities that could range from en-
dogenous RNA splicing, imaging, and localization to vari-
ous base modifications and more. The development of
rapid assembly tools for PUF specificity engineering, as
presented in this work, could play a critical role in facilitat-
ing and enhancing these endeavors.
Methods
Materials
All the chemicals and solutions were purchased from
Fisher Scientific (Pittsburgh, PA), unless noted other-
wise. Oligonucleotides were purchased from Integrated
DNA Technologies (Coralville, IA). All the enzymes
were purchased from New England Biolabs (Ipswich,
MA), unless noted otherwise.
Library creation
The amino acid and DNA sequences of all the modules
in our GG cloning library are listed in Additional file 1:
Table S1. All the amplification primers used for the cre-
ation of the library are listed in Additional file 1: Table S2.
The intermediate vector, pChlr-pNEB193, was created by
replacing the original amp resistance gene in pNEB193
(New England Biolabs) plasmid with the cam resistance
gene from pACYC (New England Biolabs) plasmid by
Gibson Assembly (GA) [45]. Plasmid pTYB3-PUM1-HD
[GenBank:D43951] was a gift of Dr. Traci M. Tanaka Hall
(Addgene plasmid 17543). The WT GG assembly modules
were amplified from pTYB3-PUM1-HD and inserted in
the SacI and HindIII sites of the intermediate vector. The
amplification primers also contained BsaI sites for subse-
quent GG cloning. Some of the modules’ 5′ and 3′ ends
were modified with silent mutations (Additional file 1:
Table S1) for the creation of non-overlapping BsaI over-
hangs. The mutant GG modules were created by GA from
the corresponding WT modules.
The receiving vector pET28-GG-PUF was GA-cloned
from the following fragments: pET28a (Novagen) digested
with NdeI and SalI, flanking PUM-HD repeats R1′ and
R8′ amplified from pTYB3-PUM1-HD, and lacZα ampli-
fied from pNEB193. BsaI sites were introduced next to
R1′ and R8′ for GG cloning of PUM-HD. The receiving
vector pCMV-TTP (C147R)-GG-PUF was cloned in
two steps. First, pCMV-TTP-GG-PUF was created byreplacing PUM-HD with a lacZα gene flanked by BsaI
sites and removal of 3 existing BsaI sites in the pCMV-
TTP (WT)-PUM-HD (see the effector plasmids section).
Next, pCMV-TTP (C147R)-GG-PUF was GA-cloned by
replacing Flag with 3xFlag and mutating the C147R of
TTP in the plasmid pCMV-TTP-GG-PUF.
For the availability to the scientific community, we are
making arrangements to deposit all the plasmids consti-
tuting the PUM-HD repeat library that we have devel-
oped here to the Addgene non-profit plasmid repository.
These plasmids should be available to researchers within
a month of the publication of this manuscript.
Reporter plasmids
pCMV-Fluc plasmid was created by amplification of the
firefly luciferase gene from pGL3 plasmid (Promega) and
insertion into SacI and KpnI sites of pCMV5 vector (a
gift of Dr. David Russell). All the pCMV-Fluc-10xPBS
plasmids, as well as pCMV-Fluc-Random were cloned
by primer-extension of 6 primers (Additional file 1:
Table S3) carrying 10 PBSs and subsequent GA-cloning
into PstI and XmaI sites of the pCMV-Fluc plasmid. The
6-18 nt spacers between the 10 PBS in the 3′ UTR of
the FL were the same in different FL-PBS sequences,
and were designed in such a way to minimize secondary
structure formation that would involve these spacers.
The pCMV-Fluc-Random was created by replacing all
the PBSs in the pCMV-Fluc-10xPBS with 10 different
scrambled sequences of 8 nt with approximately 50%
GC content. Plasmid pRL-SV40 was a gift of Dr. David J.
Shapiro.
Effector plasmids
The effector plasmid pCMV-TTP (WT)-PUM-HD was
GA-cloned from the following fragments: 2.2 kb and
2.4 kb pCMV5 fragments, GS-PUM-HD amplified from
pTYB3-PUM1-HD, and TTP-GS amplified from cDNA
(Open Biosystems catalog number MHS4768-99609440
[GenBank: BC009693.1]). pCMV-TTP (WT) and pCMV-
PUM-HD have been assembled from the same vector
backbone fragments, as well as TTP-stop or Flag-PUM-HD
fragments, respectively (for primers, see Additional file 1:
Table S4).
Golden gate assembly of mutant effector plasmids
His-tagged PUF or 3xFlag-tagged TPUF constructs for
E. coli or mammalian expression were assembled in
pET28-GG-PUF or pCMV-TTP (C147R)-GG-PUF, re-
spectively. Receiving vector of choice (50 ng) and 8
modules of choice (75 ng each) were combined with
1 μl T4 DNA ligase and 1 μl BsaI-HF in 10 μl 1× T4 DNA
ligase buffer. The reactions were cycled 10 times for 5 min
at 37°C and 10 min at 16°C, and a final incubation of
15 min at 37°C. TOP10 E. coli cells (Invitrogen) were then
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plates (Cell Media Facility, UIUC) with either kan or amp
selection, and supplemented with 10 μl 0.4 M IPTG
(GoldBio) and 40 μl 20 mg/ml Bluo-Gal (Invitrogen) for
blue-white screening. All the plasmids for E. coli expres-
sion were purified using Qiagen Qiaprep Spin Miniprep
kit, and plasmids for mammalian expression were purified
using Qiagen Plasmid Mini kit.
Protein expression and purification
His-tagged recombinant PUF proteins were expressed in
E. coli strain BL21 (DE3) (Novagen). The transformed
BL21 cultures were grown in 100 ml LB until they
reached an OD600 of 0.8, induced with 0.4 mM IPTG
and expressed at 18°C, 250 RPM overnight. Bacterial
pellets were resuspended in lysis buffer (25 mM
Tris-HCl pH 7.5, 0.3 M NaCl, 0.5% Triton (Bio-Rad),
5% glycerol (Sigma), 1 mg/ml lysozyme (Sigma), and
0.002 U/μl DNase I) and lysed by sonication. The proteins
were purified using Talon Spin Columns (Clontech),
according to manufacturer’s instructions. The eluted
protein was flash-frozen in 25% glycerol in dry ice and
stored in aliquots at -80°C.
Fluorescence polarization assay
RNA oligomers were modified with 6-carboxyfluorescein
(IDT) at the 5′-end. To determine active protein frac-
tions, we performed saturation assays for PUF proteins
against their cognate RNA (a representative saturation
curve is shown in Additional file 1: Figure S2a). High
concentrations (100 nM) of RNA oligomers in fluores-
cence anisotropy buffer (20 mM Tris-HCl pH 7.5, 0.5 mM
EDTA, 50 mM KCl, 0.1 mg/ml BSA) were mixed with
various protein concentrations (determined by Bradford
assay), and 200 μl protein-RNA mixtures were assayed
(for fluorescence polarization measurements, see below)
in black 96-well plates (Corning). The stoichiometric
points were used to estimate the active protein fractions,
which were determined to be 31% for PUF (WT), 30% for
PUF (S2), 30% for PUF (S4), 33% for PUF (S6), and 29%
for PUF (S6). Corrected active protein concentrations
were used in the subsequent binding curves for the deter-
mination of the dissociation constants KD, where RNA
oligomers (250 pM RNA for PUF (WT) and 1 nM RNA
for PUF (S2)-PUF (S8)) in the fluorescence anisotropy buf-
fer were mixed with various protein concentrations, and
duplicates of 200 μl protein-RNA mixtures were assayed.
Fluorescence polarization measurements were taken
on Tecan Infinite 200Pro using excitation and emission
wavelengths of 485 nm and 535 nm, respectively. The
fluorescence polarization values were converted to fluor-
escence anisotropy values using Equation 1, where A is
anisotropy and P is polarization. The KD was calculated
by curve fitting on Origin 8.5 using Equation 2, where Ais observed anisotropy value, Af is anisotropy of free
RNA, Ab is anisotropy of bound RNA, LT is total ligand





A ¼ Af þ Ab−Af
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Cell line transfection and dual luciferase assay
Transfection of HeLa cells (ATCC) was performed in
triplicates in a 24-well plate format with Fugene-HD
transfection reagent (Promega). Transfection mixtures
contained 150 ng FL, 2 ng pRL-SV40, and 75 ng TPUF
or equimolar amounts of other effector DNA constructs,
and empty vector pCMV5 to 500 ng total. Cells were
lysed in Passive Lysis Buffer (Promega) 48 h after trans-
fection and FL and RL activities were measured in white
96-well plates (Greiner Bio One) using Dual-Glo Lucifer-
ase Assay System (Promega) with measurements taken on
Analyst HT microplate reader at the High-Throughput
Screening Facility at UIUC.
RT-PCR
Total RNA was isolated from HeLa cells 48 hours after
transfection using the RNeasy Mini Kit (Qiagen) follow-
ing manufacturer’s instructions, and DNA was removed
from samples with Turbo DNase (Life Technologies).
RNA was reverse transcribed into cDNA with Proto-
Script First Strand cDNA Synthesis kit (NEB) using the
d(T)23VN primer. Reverse transcriptase was omitted in
control samples. RT-PCR was performed using Power
SYBR Green Master Mix (Life Technologies) with the
7900HT Fast Real-Time PCR System (Applied Biosys-
tems). Reactions were carried out in triplicates in 20 μl
reactions with 500 nM of each primer. The primer se-
quences for FL were 5′-GCGCGGAGGAGTTGTGTT
TG and 5′-ATCTTTCCGCCCTTCTTGGC; and for RL
5′-GCAGCATATCTTG AACCATTC and 5′-TTGTA
CAACGTCAGGTTTACC. ΔΔCT method was used for
RNA level analysis, where FL mRNA levels were normal-
ized to RL mRNA, and FLPBS (WT) mRNA levels were
normalized to FLRandom.
VEGF induction and ELISA assay
For hypoxia-induced VEGFA, HEK293 cells were trans-
fected in a 24-well plate format in triplicates with
Fugene-HD. Transfection mixtures contained 500 ng
TPUF DNA constructs or 350 ng pmaxGFP (Lonza) and
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fection with 500 μM CoCl2, and the supernatant was
collected for assay 24 hours after induction. For gene-
switch-induced VEGFA, HEK293 cell line with retrovi-
rally integrated DHB-inducible V24P-GS60 transcription
activator was used [40]. The cells were transfected in a
24-well plate format in triplicates as above. The cells
were induced 24 h after transfection with 100 nM DHB,
in the presence of pen/strep (Gibco). The supernatant
was collected 24 h after induction and subjected to
ELISA. The assay was performed by pre-coating the
96-well clear plate with a goat anti-mouse antibody
(Thermo Scientific) at 4°C overnight, and then follow-
ing the instructions of human VEGF DuoSet kit (R &
D Systems). The absorption readings were taken on a
SpectraMax 340PC microplate reader. The cell mono-
layer was saved for Bradford assay.
Bradford assay
The cell monolayers were lysed using RIPA lysis buffer.
The protein concentrations were measured in technical
duplicates by mixing 4 μl of cell lysate with 295 μl of
Coomassie Plus Protein Assay Reagent (Thermo Scien-
tific) in a 96-well clear plate. Quick Start Bovine Serum
Albumine Standard Set (Bio-Rad) was used to build a
protein standard curve. A595 was measured 5 min later
using a SpectraMax 340PC microplate reader. The total
protein concentrations measured by Bradford assay were
used to normalize the VEGF concentrations.
Western blotting
V24P-GS60-integrated 293 cells as well as HeLa cells
were transfected in a 6-well plate format with Fugene-
HD and 3 μg of effector plasmid. Cells were lysed using
RIPA lysis buffer (Santa Cruz Biotech). The proteins
were detected using mouse anti-Flag and anti-α-tubulin
antibodies (GeneScript) and imaged using SuperSignal West
Dura chemiluminescent substrate (Thermo Scientific).
Additional file
Additional file 1: Figure S1. Confirmation through restriction enzyme
digestion and gel-electrophoresis of GG assembled plasmids from randomly
picked clones. First and last lanes, 1 kb DNA ladder (NEB). (a) KpnI and HindIII
digestion of PUF (WT) clones assembled into pET28-GG-PUF receiving
vector. 1 kb fragment contains the full length of the assembled PUF
domain. (b) SalI and KpnI digestion of PUF (WT) clones assembled into
pCMV-TTP-GG-PUF receiving vector. 1 kb fragment contains the assembled
PUF domain region. Figure S2. Representative fluorescence anisotropy data
for RNA binding to various PUF proteins. (a) Representative saturation curve
of PUF (S4). (b) Binding curves of PUF (WT) (c) Binding curves of PUF (S2) (d)
Binding curves of PUF (S4) (e) Binding curves of PUF (S6) (f) Binding curves
of PUF (S8). Black, binding to cognate RNA. Red, binding to noncognate
RNA. Each data point is represented by the mean ± SD. KD values were
calculated from nonlinear curve fitting. Figure S3. Schematics of the
luciferase reporter assay and TPUF platform. (a) Schematic of full-length
PUM1, TTP (WT), and TPUF constructs. CCCH, zinc finger domain; GSL ,glycine-serine linker. (b) Schematic of luciferase reporters. Orange boxes,
PUF-binding sites. Figure S4. Dual luciferase assay showing TPUF (WT)
repression of FL with increasing number of PBSs in the 3′ UTR of the
reporter gene. Data represented as mean fold change relative to cells
transfected with FL with no PBS ± SD: **P ≤ 0.01 (n=3, t test). Figure
S5. Relative levels of FL/RL mRNA, normalized to FLRan/RL mRNA in
the presence of effectors. Fluorescence RT-PCR data were analyzed by
ΔΔCT method. Data represented as mean fold change relative to cells
transfected with FL Random (dashed line, unrepressed level) ± SD: n.s.,
not significant (n=3, t test). Figure S6. Dual luciferase assay showing
FL reporter repression activity of TPUF (S4). Data represented as mean
fold change relative to cells transfected with FL Random ± SD: ***P ≤ 0.001
(n=3, t test). Table S1. GG library sequences (a) Aa sequences of WT and
mutant modules. Black, WT aa. Red, mutant aa. (b) DNA sequences of WT
and mutant modules. Black, WT sequence. Red, mutant nucleotides.
Table S2. Primer list for GG library creation. Table S3. Primer list for FL
cloning. Table S4. Primer list for effector plasmid cloning.
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